Systemic Therapy for Metastatic Colon Cancer: New Frontiers

Yoanna S. Pumpalova

doi:10.1055/s-0044-1787826

Clinics in Colon and Rectal Surgery, Inhaltsverzeichnis

Clin Colon Rectal Surg 2025; 38(03): 229-236
DOI: 10.1055/s-0044-1787826

Review Article

Systemic Therapy for Metastatic Colon Cancer: New Frontiers

Autor*innen

Yoanna S. Pumpalova

¹Division of Hematology and Oncology, Department of Internal Medicine, Columbia University Irving Medical Center, New York, New York

Abstract

We have made steady gains in improving overall survival in patients with metastatic, unresectable, colon cancer in the last 5 to 10 years. The backbone of systemic treatment for most patients remains combination chemotherapy, but the field is becoming increasingly biomarker driven, with exciting new targeted therapies on the horizon. This review is organized in sections corresponding to currently relevant biomarkers in colon cancer and will summarize first-, second-, and third-line standard of care for metastatic, unresectable, colon cancer. The last section is intended to introduce the reader to promising agents and novel therapeutic strategies currently under investigation.

Keywords

metastatic colon cancer - systemic therapy - investigational agents

Volltext

Referenzen

References
1 Saltz LB, Cox JV, Blanke C. et al; Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343 (13) 905-914
2 Douillard JY, Cunningham D, Roth AD. et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355 (9209) 1041-1047
3 de Gramont A, Figer A, Seymour M. et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18 (16) 2938-2947
4 Cassidy J, Saltz L, Twelves C. et al. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann Oncol 2011; 22 (12) 2604-2609
5 Pectasides D, Papaxoinis G, Kalogeras KT. et al. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer 2012; 12: 271
6 Tournigand C, André T, Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22 (02) 229-237
7 Hurwitz H, Fehrenbacher L, Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 (23) 2335-2342
8 Saltz LB, Clarke S, Díaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26 (12) 2013-2019
9 Cremolini C, Loupakis F, Antoniotti C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16 (13) 1306-1315
10 Cremolini C, Antoniotti C, Rossini D. et al; GONO Foundation Investigators. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020; 21 (04) 497-507
11 Antoniotti C, Germani MM, Rossini D. et al. FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. Eur J Cancer 2022; 167: 23-31
12 Haraldsdottir S, Bekaii-Saab T. Integrating anti-EGFR therapies in metastatic colorectal cancer. J Gastrointest Oncol 2013; 4 (03) 285-298
13 Cunningham D, Humblet Y, Siena S. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351 (04) 337-345
14 Bylsma LC, Dean R, Lowe K, Sangaré L, Alexander DD, Fryzek JP. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: a systematic literature review and meta-analysis of patient and study characteristics. Cancer Med 2019; 8 (12) 5800-5809
15 Giusti RM, Shastri K, Pilaro AM. et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008; 14 (05) 1296-1302
16 Doleschal B, Petzer A, Rumpold H. Current concepts of anti-EGFR targeting in metastatic colorectal cancer. Front Oncol 2022; 12: 1048166
17 Dienstmann R, Connor K, Byrne AT. COLOSSUS Consortium. Precision therapy in RAS mutant colorectal cancer. Gastroenterology 2020; 158 (04) 806-811
18 Watanabe J, Muro K, Shitara K. et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 2023; 329 (15) 1271-1282
19 Ciombor KK, Strickler JH, Bekaii-Saab TS, Yaeger R. BRAF-mutated advanced colorectal cancer: a rapidly changing therapeutic landscape. J Clin Oncol 2022; 40 (24) 2706-2715
20 Kopetz S, Desai J, Chan E. et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 2015; 33 (34) 4032-4038
21 Prahallad A, Sun C, Huang S. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483 (7387) 100-103
22 Corcoran RB, Ebi H, Turke AB. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2 (03) 227-235
23 Kopetz S, Grothey A, Yaeger R. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 2019; 381 (17) 1632-1643
24 Kopetz S, Grothey A, Yaeger R. et al. BREAKWATER: randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). JCO 2021; 39 (15) TPS3619-TPS3619
25 Kopetz S, Yoshino T, Kim TW. et al. BREAKWATER: an open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC). JCO 2023; 41 (16) TPS3627-TPS3627
26 Richman SD, Southward K, Chambers P. et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol 2016; 238 (04) 562-570
27 Bekaii-Saab TS, Lach K, Hsu LI. et al. Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer: a systematic literature review and meta-analysis of clinical outcomes. Oncologist 2023; 28 (10) 885-893
28 Sartore-Bianchi A, Trusolino L, Martino C. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17 (06) 738-746
29 Sartore-Bianchi A, Lonardi S, Martino C. et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open 2020; 5 (05) e000911
30 Strickler JH, Cercek A, Siena S. et al; MOUNTAINEER investigators. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol 2023; 24 (05) 496-508
31 Modi S, Jacot W, Yamashita T. et al; DESTINY-Breast04 Trial Investigators. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022; 387 (01) 9-20
32 Siena S, Di Bartolomeo M, Raghav K. et al; DESTINY-CRC01 investigators. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol 2021; 22 (06) 779-789
33 Yoshino T, Di Bartolomeo M, Raghav K. et al; DESTINY-CRC01 investigators. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun 2023; 14 (01) 3332
34 Herzberg BO, Manji GA. KRAS: druggable at last. Oncologist 2023; 28 (04) 283-286
35 Hong DS, Fakih MG, Strickler JH. et al. KRAS^G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med 2020; 383 (13) 1207-1217
36 Skoulidis F, Li BT, Dy GK. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 2021; 384 (25) 2371-2381
37 Jänne PA, Riely GJ, Gadgeel SM. et al. Adagrasib in non-small-cell lung cancer harboring a KRAS^G12C mutation. N Engl J Med 2022; 387 (02) 120-131
38 Amodio V, Yaeger R, Arcella P. et al. EGFR blockade reverts resistance to KRAS^G12C inhibition in colorectal cancer. Cancer Discov 2020; 10 (08) 1129-1139
39 Fakih MG, Salvatore L, Esaki T. et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl J Med 2023; 389 (23) 2125-2139
40 Yaeger R, Weiss J, Pelster MS. et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med 2023; 388 (01) 44-54
41 Prager GW, Taieb J, Fakih M. et al; SUNLIGHT Investigators. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 2023; 388 (18) 1657-1667
42 Grothey A, Van Cutsem E, Sobrero A. et al; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381 (9863) 303-312
43 Li J, Qin S, Xu R. et al; CONCUR Investigators. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16 (06) 619-629
44 Dasari A, Lonardi S, Garcia-Carbonero R. et al; FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 2023; 402 (10395): 41-53
45 Diaz Jr LA, Shiu KK, Kim TW. et al; KEYNOTE-177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2022; 23 (05) 659-670
46 Andre T, Elez E, Van Cutsem E. et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study. JCO 2024; 42 (03) LBA768-LBA768
47 Sahin IH, Ciombor KK, Diaz LA, Yu J, Kim R. Immunotherapy for microsatellite stable colorectal cancers: challenges and novel therapeutic avenues. Am Soc Clin Oncol Educ Book 2022; 42 (42) 1-12
48 Le DT, Uram JN, Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372 (26) 2509-2520
49 Eng C, Kim TW, Bendell J. et al; IMblaze370 Investigators. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2019; 20 (06) 849-861
50 Overman MJ, Kopetz S, Lonardi S. et al. Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study. Ann Oncol 2016; 27: vi158
51 Chen EX, Jonker DJ, Loree JM. et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 study. JAMA Oncol 2020; 6 (06) 831-838
52 Antoniotti C, Rossini D, Pietrantonio F. et al; GONO Foundation Investigators. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 2022; 23 (07) 876-887
53 Antoniotti C, Rossini D, Pietrantonio F. et al. FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): updated and overall survival results of the phase II randomized AtezoTRIBE study. JCO 2023; 41 (16) 3500-3500
54 Mettu NB, Ou FS, Zemla TJ. et al. Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: a randomized clinical trial. JAMA Netw Open 2022; 5 (02) e2149040
55 Kawazoe A, Xu R, Passhak M. et al. LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study. Ann Oncol 2023; 34: S179
56 Fakih M, Raghav KPS, Chang DZ. et al. Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. EClinicalMedicine 2023; 58: 101917
57 Saeed A, Park R, Pathak H. et al. Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nat Commun 2024; 15 (01) 1533
58 Hecht JR, Tabernero J, Parikh AR. et al. STELLAR-303: a phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC). JCO 2023; 41 (04) TPS267-TPS267
59 El-Khoueiry AB, Fakih M, Gordon MS. et al. Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC). JCO 2023; 41 (04) LBA8-LBA8
60 Bullock A, Grossman J, Fakih M. et al. LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer. Ann Oncol 2022; 33: S376
61 Huang YH, Lee CT, Lin PC. et al. 114P The prognostic role of LAG-3 expression in metastatic colorectal cancer. Ann Oncol 2023; 34: S1514-S1515
62 Feeney K, Joubert WL, Bordoni RE. et al. RELATIVITY-123: A phase 3, randomized, open-label study of nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) versus regorafenib or trifluridine + tipiracil (TAS-102) in later-line metastatic colorectal cancer (mCRC). JCO 2023; 41 (04) TPS278-TPS278
63 Puhr HC, Ilhan-Mutlu A. New emerging targets in cancer immunotherapy: the role of LAG3. ESMO Open 2019; 4 (02) e000482
64 Serani S. BMS ends phase 3 trial of nivolumab and relatlimab in CRC. . Targeted Oncol 2023 . Accessed March 3, 2024 at: https://www.targetedonc.com/view/bms-ends-phase-3-trial-of-nivolumab-and-relatlimab-in-crc
65 Tria SM, Burge ME, Whitehall VLJ. The therapeutic landscape for KRAS-mutated colorectal cancers. Cancers (Basel) 2023; 15 (08) 2375
66 Arbour KC, Punekar S, Garrido-Laguna I. et al. 652O preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Ann Oncol 2023; 34: S458